Artesunate inhibits melanoma progression in vitro via suppressing STAT3 signaling pathway
- PMID: 33609273
- DOI: 10.1007/s43440-021-00230-6
Artesunate inhibits melanoma progression in vitro via suppressing STAT3 signaling pathway
Abstract
Background: Melanoma is a life-threatening cancer characterized with a potentially metastatic tumor of melanocytic origin. Improved methods or novel therapies are urgently needed to eliminate the development of metastases. Artesunate is a semi-synthetic derivative of artemisinin used for trarment of malaria and cancer. The purpose of this study was to investigate the anti-cancer effect of artesunate and the role on STAT3 signaling in A375 human melanoma cell line.
Methods: Melanoma cells were treated with artesunate at concentrations of 0-5 μM for 24 and 48 h. The inhibition of cell viability, colony formation, migration, invasion, adhesion, percentage of apoptotic cells, and expressions of signal transducer and activator of transcription-3 (STAT3) and related proteins were examined.
Results: Artesunate inhibited cellular proliferation of cancer cells by induction of apoptosis at sub-toxic doses. Cells treated with artesunate showed an inhibition in adhesion to extracellular matrix substrate matrigel and type IV collagen. Artesunate treatment showed a decreased cellular migration, invasion, and colony formation in melanoma cells. Artesunate also inhibited STAT3 and Src activations and STAT3 related protein expressions; such as metalloproteinase 2 (MMP-2), MMP-9, Mcl-1, Bxl-xL, vascular endothelial growth factor (VEGF), and Twist. Moreover, overexpression of constitutively active STAT3 in A375 cells attenuated the anti-proliferative, apoptotic and anti-invasive effects of artesunate.
Conclusion: The results obtained from this study demonstrated that the anticancer activity of artesunate occurred via STAT3 pathway and its target proteins. Therefore, it can be suggested that artesunate may be an important candidate molecule in the treatment of melanoma.
Keywords: Anti-apoptosis; Anti-metastasis; Artesunate; Melanoma; STAT3.
Similar articles
-
The Anti-malarial Drug Artesunate Blocks Wnt/β-catenin Pathway and Inhibits Growth, Migration and Invasion of Uveal Melanoma Cells.Curr Cancer Drug Targets. 2018;18(10):988-998. doi: 10.2174/1568009618666180425142653. Curr Cancer Drug Targets. 2018. PMID: 29692251
-
Przewaquinone A, as a natural STAT3 inhibitor, suppresses the growth of melanoma cells and induces autophagy.Phytomedicine. 2025 Jul;142:156810. doi: 10.1016/j.phymed.2025.156810. Epub 2025 Apr 26. Phytomedicine. 2025. PMID: 40311593
-
Gambogic acid exhibits anti-metastatic activity on malignant melanoma mainly through inhibition of PI3K/Akt and ERK signaling pathways.Eur J Pharmacol. 2019 Dec 1;864:172719. doi: 10.1016/j.ejphar.2019.172719. Epub 2019 Oct 3. Eur J Pharmacol. 2019. PMID: 31586634
-
STAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma.Biofactors. 2017 May 6;43(3):347-370. doi: 10.1002/biof.1345. Epub 2016 Nov 29. Biofactors. 2017. PMID: 27896891 Review.
-
Artesunate: A potential drug for the prevention and treatment from hepatitis to hepatocellular carcinoma.Pharmacol Res. 2024 Dec;210:107526. doi: 10.1016/j.phrs.2024.107526. Epub 2024 Nov 30. Pharmacol Res. 2024. PMID: 39617278 Review.
Cited by
-
Discovery and repurposing of artemisinin.Front Med. 2022 Feb;16(1):1-9. doi: 10.1007/s11684-021-0898-6. Epub 2022 Mar 15. Front Med. 2022. PMID: 35290595 Free PMC article. Review.
-
Serum vascular endothelial growth factor is associated with cardiovascular involvement and response to therapy in Erdheim-Chester disease.Haematologica. 2023 Feb 1;108(2):513-521. doi: 10.3324/haematol.2022.280755. Haematologica. 2023. PMID: 36005561 Free PMC article.
-
Anti-tumor mechanism of artesunate.Front Pharmacol. 2024 Oct 25;15:1483049. doi: 10.3389/fphar.2024.1483049. eCollection 2024. Front Pharmacol. 2024. PMID: 39525639 Free PMC article. Review.
-
Bibliometric and Visualized Analysis of Artemisinin and Its Derivatives in Cancer.Drug Des Devel Ther. 2025 Jun 30;19:5517-5538. doi: 10.2147/DDDT.S514219. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40620464 Free PMC article.
-
Artesunate regulates malignant progression of breast cancer cells via lncRNA TUG1/miR-145-5p/HOXA5 axis.PLoS One. 2025 Aug 4;20(8):e0329490. doi: 10.1371/journal.pone.0329490. eCollection 2025. PLoS One. 2025. PMID: 40758729 Free PMC article.
References
-
- Chopra A, Sharma R, Rao UNM. Pathology of melanoma. Surg Clin North Am. 2020;100:43–59. - PubMed
-
- Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. Vivo. 2014;28:1005–11.
-
- Bertolotto C. Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica (Cairo). 2013;2013:635203.
-
- Shellenberger R, Nabhan M, Kakaraparthi S. Melanoma screening: a plan for improving early detection. Ann Med. 2016;48:142–8. - PubMed
-
- Momtaz S, Niaz K, Maqbool F, Abdollahi M, Rastrelli L, Nabavi SM. STAT3 targeting by polyphenols: novel therapeutic strategy for melanoma. BioFactors. 2017;43:347–70. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous